Estrogen-Dependent Switch Tempers Killing Activity of Immune CellsAugust 10, 2009The sex hormone estrogen tempers the killing activity of a specific group of immune cells, the cytotoxic T cells (CTLs), which are known to attack tumor cells and cells infected by viruses. The key player in this process is a cytotoxic T cell molecule which has been known for a long time and which scientists have named EBAG9. Cancer researchers Dr. Constantin Rüder and Dr. Armin Rehm together with immunologist Dr. Uta Höpken of the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch and Charité - University Medicine Berlin, Germany, have now unraveled the function of EBAG9. Modulated by estrogen, EBAG9 tempers the activity of CTLs. In the absence of EBAG9, the activity of CTLs is enhanced (Journal of Clinical Investigation, Vol. 119, No. 8, pp 2184-2203, August 3, 2009)*. The sex hormone estrogen plays a critical role in the regulation of growth and the development of cells. It is also crucial for cell-type-specific gene expression in various tissues. Deregulation of this system results in breast and ovarian cancer. Those tumors are successfully treated with drugs such as tamoxifen. Researchers suggest that this drug inhibits tumor growth by blocking the estrogen receptors of the tumor cells. However, up to now it has been unclear what effect this inhibition has on the immune system. In a previous study, Japanese researchers detected large amounts of EBAG9 in estrogen-dependent tumors. Dr. Rehm and his colleagues wondered what effect elevated levels of estrogen would have on cytotoxic T cells that attack tumors. They assumed that EBAG9 could transmit this effect of estrogen and therefore wanted to know what would happen if they knocked out the gene for EBAG9 in mice. After knocking out the gene for EBAG9, they found that in the absence of EBAG9 the "brake" of the immune cells is loosened. The immune cells can release much more of the tumor-killing enzymes than in the presence of EBAG9. The deathly harbingers are stored in granules (secretory lysosomes) in the cytotoxic T cells. They have greater quantities of these granules at their disposal once the blockage of the immune cells through EBAG9 is lifted. These findings of the researchers in Berlin may also explain why drugs like tamoxifen act on tumor cell growth. One argument is that once the estrogen receptors of the tumor cells are inhibited by the drug, the sex hormone can no longer promote tumor growth. At the same time EBAG9 can no longer inhibit the cytotoxic T cells. The immune cells are ready to attack and destroy the tumor cells. "In this way, tamoxifen not only inhibits tumor growth but may also be able to enhance the effect of the immune system," Dr. Rehm said. His working hypothesis is that EBAG9 acts as a molecular switch which regulates the immune cells. As a next step, he and his colleagues plan to study cytotoxic T cells from patients with estrogen-dependent tumors to see if EBAG9 levels are increased. Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch |
|||||||||||||||||||||
| Related Immune Cells Current Events and Immune Cells News Articles New findings suggest strategy to help generate HIV-neutralizing antibodies New discoveries about anti-HIV antibodies may bring researchers a step closer to creating an effective HIV vaccine, according to a new paper co-authored by scientists at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Sweet -- sugared polymer a new weapon against allergies and asthma Scientists at Johns Hopkins and their colleagues have developed sugar-coated polymer strands that selectively kill off cells involved in triggering aggressive allergy and asthma attacks. Scientists visualize how bacteria talk to one another Using imaging mass spectrometry, researchers at the University of California, San Diego have developed tools that will enable scientists to visualize how different cell populations of cells communicate. Key player identified in cascade that leads to hypertension-related kidney damage A key player in a cascade that likely begins with stress and leads to high blood pressure and kidney damage has been identified by researchers who say the finding may lead to better ways to control both. Genetic links to fungal infection risk identified Two genetic mutations that may put individuals at increased risk of fungal infections have been identified by scientists from UCL and Radboud University, increasing understanding about the genetic basis of these infections and potentially aiding the development of new treatments. Study shows how carbon nanotubes can affect lining of the lungs Carbon nanotubes are being considered for use in everything from sports equipment to medical applications, but a great deal remains unknown about whether these materials cause respiratory or other health problems. Manipulating Brain Inflammation May Help Clear Brain of Amyloid Plaques, Mayo Clinic Researchers Say In a surprising reversal of long-standing scientific belief, researchers at the Mayo Clinic campus in Florida have discovered that inflammation in the brain is not the trigger that leads to buildup of amyloid deposits and development of Alzheimer's disease. Stanford study identifies cellular mechanism that causes lupuslike symptoms in mice Macrophages, the scavenger cells of the body's immune system, are responsible for disposing of dying cells. Stanford University School of Medicine researchers have identified one pathway in this important process in mice that, if disrupted, causes a lupuslike autoimmune disease. New chromosomal abnormality identified in leukemia associated with Down syndrome Researchers identified a new chromosomal abnormality in acute lymphoblastic leukemia (ALL) that appears to work in concert with another mutation to give rise to cancer. This latest anomaly is particularly common in children with Down syndrome. Research shows treating HIV-AIDS with interleukin-2 is ineffective An international research team has demonstrated that treating HIV-AIDS with interleukin-2 (IL-2) is ineffective. As a result, the researchers recommend that clinical trials on this compound be stopped. More Immune Cells Current Events and Immune Cells News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||